Abstract Number: 006 • 2020 Pediatric Rheumatology Symposium
Increasing Rates of Standardized Depression Screening in Youth with Systemic Lupus Erythematosus in a Pediatric Rheumatology Clinic
Background/Purpose: Depression is common among youth with SLE. Early identification and treatment of depression has the potential to improve health outcomes for youth with SLE.…Abstract Number: 031 • 2020 Pediatric Rheumatology Symposium
Exome Sequencing for Early Pediatric Systemic Lupus Erythematosus: Standard of Care in 2020?
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with multifactorial etiology. Identification of monogenic causes of pediatric SLE (pSLE) has yielded important insights…Abstract Number: 071 • 2020 Pediatric Rheumatology Symposium
Patient Reported Outcomes and Resilience in Pediatric Systemic Lupus Erythematosus
Background/Purpose: It has been established that pediatric Systemic Lupus Erythematous (pSLE) is associated with lower health-related quality of life (HRQOL); however, there are few studies…Abstract Number: 088 • 2020 Pediatric Rheumatology Symposium
Sun Protection Use in Patients Followed in a Pediatric Rheumatology Clinic in an Urban Setting
Background/Purpose: Exposure to sunlight has been implicated as a major contributing factor in the pathogenesis of systemic lupus erythematosus (SLE) and juvenile dermatomyositis (JDM). Despite…Abstract Number: 168 • 2020 Pediatric Rheumatology Symposium
Examining the Role of IFN-I and Langerhans Cell ADAM17 in Lupus Photosensitivity
Background/Purpose: Photosensitivity resulting in inflammatory skin lesions is a hallmark of cutaneous lupus. Lesions can be disfiguring and have a negative impact on quality of…Abstract Number: 689 • 2019 ACR/ARP Annual Meeting
Patterns of High Disease Activity Status and Outcomes in Systemic Lupus Erythematosus
Background/Purpose: High Disease Activity Status (HDAS), defined as ever attainment of SLEDAI-2k of 10 or greater, may be a useful indicator of overall disease severity in…Abstract Number: 1199 • 2019 ACR/ARP Annual Meeting
Improving Rates of Cervical Cancer Screening and HPV Vaccination in Patients with Lupus
Background/Purpose: Patients with lupus have higher rates of cervical dysplasia and pre-malignant cervical lesions. At our institution, an urban referral center for patients with lupus, rates…Abstract Number: 1734 • 2019 ACR/ARP Annual Meeting
Low Bone Mineral Density Was Associated with Lupus Nephritis Irrespective of Duration on Steroid Treatment in a Large Observational Study of Juvenile Systemic Lupus Erythematosus Patients
Background/Purpose: An estimated 10-20% of all patients with systemic lupus erythematosus (SLE) develop clinical disease before the age of 18 years and are therefore classified…Abstract Number: 2584 • 2019 ACR/ARP Annual Meeting
Management of Cutaneous Manifestations of Lupus Erythematosus: A Systematic Review
Background/Purpose: Cutaneous lupus erythematosus (CLE), occurring with or without systemic lupus erythematosus (SLE), is a group of inflammatory skin diseases that can be very debilitating,…Abstract Number: 691 • 2019 ACR/ARP Annual Meeting
Adjusted GAPSS in Systemic Lupus Erythematosus Patients in Argentina
Background/Purpose: Assessment of risk both for pregnancy morbidity and thrombosis in the presence of anti-phospholipid antibodies (aPL) is still a challenge. The Global Antiphospholipid Syndrome…Abstract Number: 1561 • 2019 ACR/ARP Annual Meeting
Decreased Nocturnal Blood Pressure Dipping in Patients with Systemic Lupus Erythematosus: Association with Markers of Inflammation
Background/Purpose: Blood pressure follows a circadian rhythm; usually systolic blood pressure (SBP) drops by more than 10% during the night. Absence of this phenomenon, known…Abstract Number: 1786 • 2019 ACR/ARP Annual Meeting
Surrogate Pathways of Complement Activation in Novel Polygenic SLE-like Models of Kidney Injury
Background/Purpose: Lupus nephritis (LN) is a major contributor to morbidity and mortality in systemic lupus erythematosus (SLE). Defective clearance of apoptotic cells (AC), autoantibodies, and…Abstract Number: 2782 • 2019 ACR/ARP Annual Meeting
Comparative Risks of Cardiovascular Disease Among SLE Patients Receiving Immunosuppressive Medications
Background/Purpose: Human studies examining cardiovascular disease (CVD) risk associated with immunosuppressants (IS) have been limited, but mycophenolate mofetil (MMF) was shown to suppress vascular smooth muscle…Abstract Number: 694 • 2019 ACR/ARP Annual Meeting
Body Mass Index at Time of Diagnosis Is Predictive of Future Disease Activity in SLE
Background/Purpose: Obesity is more common in patients with SLE compared to the general population. The prevalence of obesity among SLE patients is between 28 and…Abstract Number: 1568 • 2019 ACR/ARP Annual Meeting
High Risk Low Attenuation Non-Calcified Coronary Plaque in Lupus vs. Controls
Background/Purpose: The presence of low attenuation noncalcified plaque (< 30 Haunsfield units) is one of the most characteristic vessel changes in unstable coronary plaques. Low-attenuation…
- 1
- 2
- 3
- …
- 31
- Next Page »